Product Introduction
Bioactivity


英文名: Carbimazole

描述: Carbimazole (Athyromazole) 是咪唑类甲状腺拮抗试剂，在体内快速转化为 MMI 而发挥作用，在体外可转化为甲咪唑，可用于 Graves 病的研究。

激酶实验: In vitro kinase assays: with purified proteins, recombinant S6 protein and recombinant active P70S6K are incubated in 1x kinase buffer with various amount of HCQ or RAD001 in the presence (25 μM) or absence of ATP for 30 minutes at 30°C. Total and phosphorylated S6 at ser235/236 and ser240/244 are detected by western analysis using phosphospecific antibodies. Note that recombinant GST-tagged S6 (53 kd) is distinguished from endogenous S6 (32 kd) on the western blot.

体内活性: Carbimazole被人体吸收后转化为甲巯咪唑,产生抗甲状腺作用,作用于抗甲亢(过度产生甲状腺激素)和甲状腺毒症(甲状腺炎症)。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 12 mg/mL (64.4 mM)
DMSO : 60 mg/mL (322.18 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: Carbimazole | antithyroid agent | MMI | inhibit | Graves' disease | Inhibitor | methimazole

相关产品: Liothyronine | Sobetirome | REVERSE T3 | Protirelin Acetate(24305-27-9 free base) | Eprotirome | L-Thyroxine sodium | L-Thyroxine sodium salt pentahydrate | (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate | Protirelin | KAT681

相关库: Drug Repurposing Compound Library | Approved Drug Library | Hematopoietic Toxicity Compound Library | ReFRAME Related Library | Drug-Fragment Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Metabolism Disease Compound Library | Endocrinology-Hormone Compound Library | Orally Active Compound Library | Bioactive Compound Library